Lunch @UCSF with Hope Rugo – Biosimilars: boon for the developing world

Lunch @UCSF with Hope Rugo – Biosimilars: boon for the developing world

Biological agents, or biologics, are widely used to treat cancer and to manage treatment-related side effects. Unlike small-molecule generic drugs, exact copies of these biologics are impossible to produce because they are large, highly complex molecules produced in living cells. Biosimilars are biological products that are highly similar to a licensed biological product, with no clinically meaningful differences in terms of safety, purity, or potency.

Biosimilars have the potential to provide savings to healthcare systems and to make important biological therapies widely accessible to a global population. Biosimilars for commonly used oncology drugs are expected to reach the market in the near future, and clinicians will need to decide whether to consider biosimilars as alternatives to these existing products.

Join Rugo to learn about several biosimilars that are currently in development for cancer treatment, and how the trend toward biosimilars may have benefits for oncologists and patients in the developing world.